NCM
CGON icon

Nantahala Capital Management’s CG Oncology CGON Stock Holding History

Nantahala Capital Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.35M Sell
49,449
-60,000
-55% -$3.4M 0.12% 114
2025
Q4 		$4.54M Hold
109,449
– – 0.15% 104
2025
Q3 		$4.41M Buy
+109,449
New +$3.18M 0.15% 109

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nantahala Capital Management's CGON Position: Q1 2026 in Review

Nantahala Capital Management reduced its CG Oncology (CGON) stake by 55% in Q1 2026, selling an estimated $3.4M and leaving 49,449 shares worth $3.35M. The position accounts for 0.12% of the portfolio, ranked #114.

Nantahala Capital Management first reported a position in CGON in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.54M in Q4 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Nantahala Capital Management held 49,449 shares of CG Oncology worth $3.35M as of Q1 2026.
  • Nantahala Capital Management sold 60,000 CG Oncology shares in Q1 2026, an estimated $3.4M.
  • CG Oncology made up 0.12% of Nantahala Capital Management's portfolio in Q1 2026, its #114 holding.
  • Nantahala Capital Management first reported a position in CG Oncology in Q3 2025 and has held it in 3 quarters since.
  • Nantahala Capital Management's CG Oncology position peaked at $4.54M in Q4 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.